SCHEMBL7799351

SCHEMBL7799351

CN(Cc1ccc(F)cc1)C(=O)c1cnc2c3c(ccc2c1)C(=O)C([N+](=O)[O-])C=N3

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 1/20 0.37
NSD2 O96028 1/20 0.37
KMT2A Q03164 1/20 0.36
USP1 O94782 2/20 0.36
MCHR1 Q99705 2/20 0.35
HTR2C P28335 1/20 0.35
ALDH1A1 P00352 2/20 0.35
HTT P42858 1/20 0.35
POLB P06746 1/20 0.34
ATM Q13315 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.33
LIMK2 P53671 1/20 0.33
STAMBP O95630 1/20 0.33
COPS5 Q92905 1/20 0.33
LMNA P02545 1/20 0.32
MAPT P10636 1/20 0.32
ROCK2 O75116 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7802386 0.87 KMT2A (0.40) RAB9ANSD2KMT2AUSP1MCHR1
SCHEMBL7802357 0.82 KMT2A (0.37) RAB9ANSD2KMT2AUSP1MCHR1
SCHEMBL7799334 0.80 KMT2A (0.38) KMT2AALDH1A1LIMK2LMNAROCK2
SCHEMBL7793527 0.79 USP1 (0.41) RAB9ANSD2KMT2AUSP1MCHR1
SCHEMBL7793469 0.79
SCHEMBL7799067 0.79 HCAR3 (0.33) ALDH1A1POLBMAPT
SCHEMBL7799119 0.78 MEN1 (0.43) KMT2AALDH1A1ATMLIMK2ROCK2
SCHEMBL6985187 0.78 PSMD14 (0.40) ALDH1A1LMNA
SCHEMBL6981930 0.76 MAOB (0.43) RAB9AKMT2AALDH1A1POLBLMNA
SCHEMBL7793529 0.76 RIPK1 (0.37) KMT2AMCHR1HTR2CATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1027351-A1 PHENANTHROLINE DERIVATIVES FIBROGEN, INC. (US) 2000-08-16 EP claimed
WO-1999021860-A1 PHENANTHROLINE DERIVATIVES FIBROGEN, INC. (US) 1999-05-06 WO claimed
US-20010001101-A1 Phenanthroline derivatives ZENECA LIMITED 2001-05-10 US disclosed
EP-1027351-A1 PHENANTHROLINE DERIVATIVES FIBROGEN, INC. (US) 2000-08-16 EP disclosed
WO-1999021860-A1 PHENANTHROLINE DERIVATIVES FIBROGEN, INC. (US) 1999-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010001101-A1 Phenanthroline derivatives H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, COL1A1, COL2A1 RAB9A 1686/4885NSD2 1557/4885KMT2A 1250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.